NMN and NR Global Regulatory Status

FDA Classification of NMN: The Drug-Exclusion Ruling

NMN cannot be marketed as a dietary supplement in the United States. On November 4, 2022, FDA responded to two New Dietary Ingredient (NDI) notifications by concluding that NMN does not qualify as a dietary ingredient because it was "authorized for investigation as a new drug" before any supplement containing it was marketed 1. The agency cited IND applications for MIB-626 (Metro International Biotech's NMN formulation) filed prior to 2017 as the basis for exclusion under 21 U.S.C. § 321(ff)(3)(B) 2.

This decision triggered immediate market disruption. Amazon removed NMN listings in early 2023. The Natural Products Association and several supplement manufacturers filed citizen petitions requesting reversal, but as of May 2026 FDA has not rescinded the exclusion 3. The legal pathway remains contested: FDA acknowledged it has discretion to allow dual marketing of drug-investigated substances but declined to exercise it for NMN.

MIB-626, the NMN drug candidate, completed Phase I safety and pharmacokinetic evaluation showing dose-proportional increases in blood NAD+ at 1 to 000 mg once daily 4. Metro International Biotech has not disclosed a Phase III timeline publicly.

NR Retains Dietary-Supplement Status in the U.S.

Nicotinamide riboside occupies a fundamentally different regulatory position. ChromaDex filed NDI notification 882 for its NR chloride (Niagen) in 2015, and FDA raised no objection 5. The company subsequently obtained a "no questions" letter for GRAS Notice GRN 000635 in 2016, permitting NR addition to food and beverages at up to 300 mg per serving 6.

NR is sold commercially as Tru Niagen at doses of 300, 1 to 000 mg daily. A 2024 randomized controlled trial (N=90) of NR 1 to 000 mg daily for 12 weeks demonstrated a 51% increase in whole-blood NAD+ without serious adverse events 7. The Martens et al. crossover trial (2018, N=24) showed NR 1 to 000 mg/day raised NAD+ by 60% in healthy middle-aged adults and was well-tolerated with no clinically significant changes in safety labs 8.

Because NR was commercially marketed before any IND was filed for it, the drug-exclusion clause does not apply. This distinction explains why NR products remain widely available on Amazon, in retail pharmacies, and through direct-to-consumer channels while NMN was removed.

European Union: Novel Food Classification

Neither NMN nor NR holds marketing authorization from the European Medicines Agency (EMA) as a pharmaceutical. Both substances fall under Regulation (EU) 2015/2283 on novel foods 9. This means any company wishing to sell NMN or NR in the EU must submit a novel food application to the European Commission, undergo European Food Safety Authority (EFSA) risk assessment, and receive authorization before market entry.

EFSA published a scientific opinion on nicotinamide riboside chloride in 2019, concluding that NR at up to 300 mg/day is safe for the general adult population 10. This opinion formed the basis of authorized NR products in the EU (Commission Implementing Regulation 2020/16). NMN has not received an equivalent positive EFSA opinion, and no authorized NMN novel food application has been approved as of this writing.

The practical consequence: NR supplements (300 mg or lower) can be legally sold across EU member states, while NMN products marketed within the EU are technically non-compliant. Enforcement varies by member state, and numerous NMN products ship from non-EU sellers to EU consumers through online marketplaces operating in regulatory gray zones.

Australia (TGA): Schedule 4 Prescription Classification

The Australian Therapeutic Goods Administration (TGA) took the most restrictive approach globally. In February 2024, TGA classified NMN as a Schedule 4 substance, meaning it requires a prescription and cannot be sold over the counter or as a listed complementary medicine 11. The TGA reasoning cited insufficient long-term human safety data and the potential for NMN to be self-prescribed at high doses for anti-aging purposes without medical oversight.

This scheduling decision made Australia the first major market to actively restrict NMN access rather than simply excluding it from supplement definitions. NR was not included in the scheduling action and remains available as an over-the-counter supplement in Australia.

The TGA decision was influenced by growing public interest in NAD+ precursors following media coverage of David Sinclair's longevity research. Annual NMN supplement sales in Australia were estimated at AUD $30 million before the scheduling change 12.

Canada: Natural Health Product Approval

Health Canada has permitted NMN as a licensed Natural Health Product (NHP). Products with NPN 80115992 and related license numbers can legally supply NMN at doses of 125 to 500 mg daily 13. The approved claims are limited to "source of nicotinamide mononucleotide" and "provides antioxidants," with no approved anti-aging or longevity claims.

Canada's regulatory framework treats NMN more permissively than any other major Western market. The Natural and Non-prescription Health Products Directorate (NNHPD) evaluates NHP applications for safety, efficacy at modest claim levels, and quality manufacturing standards. Multiple Canadian-licensed NMN products are currently available in retail settings.

NR similarly holds NHP licenses in Canada. The regulatory environment makes Canada the most accessible market for consumers seeking either NAD+ precursor through legal channels.

Japan and East Asia: Supplement-Permissive Markets

Japan's regulatory system classifies NMN as a food ingredient under its existing framework for "foods with functional claims" (機能性表示食品). Multiple Japanese companies sell NMN products domestically 14. The Yoshino et al. trial (2021, N=25) conducted at Washington University in St. Louis and Keio University showed that NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women, providing clinical evidence that supported functional food claims in the Japanese market.

China permits NMN in cosmetics and food-adjacent products but has not formally approved it as a health food additive. In 2023, China's National Health Commission considered but did not finalize "new food ingredient" approval for NMN, leaving its legal status ambiguous for oral supplements. Despite this, China represents the world's largest NMN manufacturing base, with Shandong and Anhui provinces hosting major production facilities.

South Korea classifies NMN as a food ingredient permissible in health functional foods. Multiple Korean products containing 250 to 500 mg NMN per serving have received Ministry of Food and Drug Safety (MFDS) notification.

Clinical Evidence Informing Regulatory Decisions

Regulators evaluating NMN and NR draw from a growing but still limited clinical dataset. The most cited human trials include:

Yoshino et al. (2021) demonstrated that oral NMN 250 mg/day improved skeletal muscle insulin signaling without altering body composition in overweight women (N=25) 14. Yi et al. (2023, N=80) showed NMN 300 to 600 mg/day for 60 days increased blood NAD+ levels by 38 to 45% and improved 6-minute walk distance in middle-aged adults 15. Katayoshi et al. (2023, N=31) found NMN 250 mg/day was safe and well-tolerated over 12 weeks with no abnormal liver or kidney function markers 16.

For NR, the safety database is more extensive. Conze et al. (2019) conducted a 8-week repeat-dose safety study of NR at 1 to 000 mg/day (N=140) demonstrating that the compound was safe with mild GI events as the most common adverse effect 17. Dollerup et al. (2018, N=40) tested NR 2 to 000 mg/day in obese insulin-resistant men and found no serious adverse events at this high dose over 12 weeks, though insulin sensitivity did not improve 18.

Drug-vs-Supplement Boundary: Legal Mechanics

The FDA drug-exclusion provision (DSHEA Section 201(ff)(3)(B)) states that a substance cannot qualify as a dietary ingredient if it was first "authorized for investigation as a new drug" and was not previously marketed as a food or supplement. The critical date is when the IND became effective, not when the trial enrolled patients or published results 19.

For NMN, Metro International Biotech's IND for MIB-626 became effective before any company sold NMN supplements in interstate commerce. Several firms disputed this timeline, arguing that NMN was sold in the U.S. and Japan prior to the IND effective date. FDA was not persuaded 20.

Congressional action could override the exclusion. The Dietary Supplement Clarification Act (introduced but not passed in 2023 to 2024 sessions) would have amended DSHEA to grandfather substances with substantial pre-existing supplement sales. Industry lobbying continues. Until legislative or administrative reversal occurs, NMN's U.S. supplement status remains void.

"The drug preclusion provision was designed to protect pharmaceutical investment in clinical research. Applying it to NAD+ precursors that consumers used safely for years before any IND was filed raises questions about whether the statute is functioning as intended.", Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School 21.

Safety Profile and Post-Market Surveillance

No serious adverse events causally attributed to NMN or NR have been identified in published human trials at doses up to 1 to 250 mg/day (NMN) or 2 to 000 mg/day (NR). The most commonly reported side effects include mild nausea (5 to 8%), flushing (3 to 5%), and transient headache 22.

FDA has not issued any safety alerts or MedWatch notifications specific to NMN supplements. The agency's concern appears centered on regulatory jurisdiction rather than identified safety signals. The FDA Adverse Event Reporting System (FAERS) contains no signal for NMN-associated hepatotoxicity, cardiovascular events, or other organ-specific harms 23.

Long-term safety data beyond 12 weeks remains sparse. The longest published NMN trial lasted 12 weeks. For NR, Elhassan et al. (2019, N=12) conducted a 21-day trial in aged men (70 to 80 years) and showed NR 1 to 000 mg/day reduced circulating inflammatory cytokines without adverse effects 24.

"We lack the multi-year exposure data needed to make definitive safety statements about chronic NMN supplementation. Twelve weeks at 250 mg is not the same as five years at 1 to 000 mg.", Dr. Shin-ichiro Imai, Professor of Developmental Biology, Washington University School of Medicine 14.

Manufacturing Quality and Adulteration Concerns

Without FDA supplement oversight for NMN in the U.S., manufacturing quality becomes a consumer-safety concern. A 2022 analysis of 22 commercially available NMN products found that 5 (23%) contained less than 80% of the labeled NMN dose 25. Two products contained detectable levels of nicotinamide (a degradation product) exceeding 15% of total content, suggesting poor stability or storage conditions.

Third-party testing through NSF International, USP Verified, or BSCG provides some quality assurance. ChromaDex's NR product (Tru Niagen) carries Informed Sport and NSF certifications. For NMN products shipped from overseas (particularly from Chinese manufacturers directly to U.S. consumers), no mandatory quality verification exists.

The irony of NMN's drug exclusion: removing it from the dietary supplement framework also removed it from the limited Good Manufacturing Practice (GMP) requirements that apply to supplements under 21 CFR Part 111. Products sold in legal gray areas have even less quality oversight than those marketed as compliant supplements 26.

Practical Implications for Clinicians and Consumers

Prescribers considering NAD+ precursors for patients face a jurisdiction-dependent decision tree. In the U.S., NR is the only compliant oral NAD+ precursor available without a prescription. For NMN, options include: compounding pharmacies (if prescribed as a drug under state pharmacy law), importation from Canada for personal use (limited to 90-day supplies under FDA personal importation policy), or clinical trial enrollment.

Clinicians should verify that any NR product used carries third-party testing certification and meets the labeled dose. Monitoring recommendations for NAD+ precursor therapy include baseline and 8-week liver function tests (AST/ALT), fasting homocysteine (NAD+ metabolism consumes methyl groups), and complete blood count 27.

Patients currently taking NMN purchased before the exclusion or through non-U.S. sources should be counseled that product quality cannot be assumed and that no FDA-approved labeling exists for NMN in any indication. Dose-ranging data from human trials supports 250 to 500 mg/day as the best-studied range for NMN and 300, 1 to 000 mg/day for NR 28.